LN and type IV collagen were always present around morphologically well-differentiated duct-like structures in all tumors studied. BM interruption could not be seen in the malign tumors, on the contrary BM production was evident, which is probably related to invasion. FN was present in the stroma of all tumors, but TN was mostly observed in less differentiated and higher degree of malignancy tumors, such as solid ACC.
Collagen IV and laminin, and their integrin ligands, are useful in demonstrating that neoplastic ductal units of PLGA are composed of a single cell layer, being distinct from ACC which contains structures composed of two layers of neoplastic cells.
Data de entrada do artigo: 04/08/2013 Data de aceite do artigo: 05/12/2013 Introdução: Os pacientes com doença renal crônica têm condições sistêmicas e orais características, que exigem precauções especiais durante o tratamento odontológico. Os medicamentos devem ser administrados com cautela e os pacientes que são submetidos à diálise devem receber atenção especial. Antes do início de qualquer tratamento odontológico, o cirurgião dentista deve consultar o médico do paciente a respeito das precauções específicas. Um plano de tratamento deve ser constituído, protegendo contra possíveis riscos. Objetivo: Descrever as manifestações sistêmicas e orais, a fisiopatologia e considerações gerais e farmacológicas para o tratamento oral de pacientes que apresentam doença renal crônica. Materiais e Métodos: Uma revisão analítica, retrospectiva e descritiva da literatura do tópico foi realizada utilizando informações e protocolos atualizados. Conclusão: Para o tratamento desses pacientes, os clínicos devem ter a capacidade de reconhecer o nível de risco, estar cientes dos protocolos farmacológicos, características do atendimento clínico e alterações psicológicas que esses pacientes podem apresentar. É importante também reconhecer as diferentes necessidades e os ajustes que devem ser feitos individualmente para cada um dos casos. Palavras-chave: nefropatias; insuficiência renal; assistência odontológica. RESUMO Introduction: Patients with chronic renal disease have specific systemic and oral conditions, which require special precautions during oral treatment. Drugs must be administered with caution and patients undergoing dialysis must receive special consideration. Before any oral treatment, the dentist should consult the patient's physician about specific precautions. A treatment plan should be built in order to protect from potential risks. Objective: To describe the physiopathology, systemic and oral manifestations, as well as overall and pharmacological considerations for the oral treatment of patients with chronic renal disease. Materials and Methods: An analytical retrospective descriptive literature review on the subject was performed using up-to-date information and protocols. Conclusion: For the treatment of patients with chronic renal disease, clinicians should be capable to recognize the level of risk in those individuals, be aware of pharmacological protocols, clinical management and psychological changes that these patients may present. It is also important to recognize the different necessities and adjustments that must be made for each case individually.
Based on generalized estimating equations, it was concluded that the probability of correct diagnosis does not depend on the kind of lesion, on the radiographic technique or on the specialization of the examiner. In view of the differing opinions of the specialists regarding the diagnostic validity of some software features available and of the results obtained in indirect digital technique, it may be reasonable to reconsider its use for diagnosis of bone pathology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.